Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies
{{output}}
Background and aim: Elranatamab is a bispecific antibody currently approved in the United States (US) for the treatment of relapsed/refractory multiple myeloma (MM). Given its recent approval, real-world data are limited. ... ...
